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Abstract
Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms 
(SNPs) in six genes that are associated with childhood acute lymphoblastic leukemia (ALL). A 
lead SNP was found to occur on chromosome 9p21.3, a region that is deleted in 30% of childhood 
ALLs, suggesting the presence of causal polymorphisms linked to ALL risk. We used SNP 
genotyping and imputation-based fine-mapping of a multiethnic ALL case-control population 
(Ncases=1464, Ncontrols=3279) to identify variants of large effect within 9p21.3. We identified a 
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CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-
fold increased risk of ALL in children of European-ancestry (OR=2.99; P=1.51×10−9) and 
Hispanic children (OR=2.77; P=3.78×10−4). Moreover, of 17 patients whose tumors displayed 
allelic imbalance at CDKN2A, 14 preferentially retained the risk allele and lost the protective 
allele (PBinomial=0.006), suggesting that the risk allele provides a selective advantage during tumor 
growth. Notably, the CDKN2A variant was not significantly associated with melanoma, 
glioblastoma, or pancreatic cancer risk, implying that this polymorphism specifically confers ALL 
risk but not general cancer risk. Taken together, our findings demonstrate that coding 
polymorphisms of large effect can underlie GWAS “hits” and that inherited polymorphisms may 
undergo directional selection during clonal expansion of tumors.
INTRODUCTION
The etiology of childhood acute lymphoblastic leukemia (ALL) is multifactorial, influenced 
by environmental stimuli, immune development, and genetic factors (1). Recent genome-
wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) 
in six genes that modify ALL risk, including ARID5B, IKZF1, CEBPE, CDKN2A, PIP4K2A 
and GATA3 (2, 3). With the exception of rs3824662 in GATA3, which confers 3-fold 
increased risk of Philadelphia chromosome-like ALL (4), GWAS of ALL have not identified 
variants of large effect sizes (odds ratio range: 1.30-1.86)(2).
The lead SNP on 9p21.3 from previous ALL GWAS, rs3731217, is located in intron 1 of the 
tumor suppressor gene CDKN2A within a linkage block containing another tumor suppressor 
gene (CDKN2B) and a functional non-coding RNA (CDKN2B-AS1)(5). Inherited SNPs in 
this linkage block are associated with several additional cancers, including: melanoma, 
glioblastoma, nasopharyngeal carcinoma, and squamous cell lung cancer (6-9). Somatic 
alteration of 9p21.3 via focal and whole-arm deletions, as well as copy-neutral loss of 
heterozygosity (LOH), occurs in many cancers and in ~30% of childhood ALL cases (10). 
The co-occurrence of inherited (i.e. germline) and acquired (i.e. somatic) cancer-associated 
variants on 9p21.3 suggests that heritable risk alleles in this region may undergo selection 
during tumor evolution, a phenomenon known as preferential allelic imbalance (PAI).
We sought to identify causal polymorphisms underlying the childhood ALL association 
peak near CDKN2A by performing SNP genotyping and imputation-based fine-mapping of 
the region in a multi-ethnic case-control population. The discovery sample for our fine-
mapping analysis included 321 Hispanic children with ALL and 454 Hispanic control 
children from the California Childhood Leukemia Study (CCLS). Validation fine-mapping 
was performed in an independent set of 980 European-ancestry children with ALL and 2624 
control children from the Children's Oncology Group (COG) and the Wellcome Trust Case-
Control Consortium (WTCCC). Following association testing and bioinformatics analyses 
of SNP function, the top SNP underwent validation genotyping in a third independent ALL 
case-control set. Using a novel application of droplet-digital PCR (ddPCR), we further 
assessed whether the newly identified risk allele underwent PAI in ALL tumor samples.
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MATERIALS AND METHODS
Figure 1 and Supplementary Table 1 summarize the study design and study populations, 
respectively. This study was approved and reviewed by all collaborating institutions, 
including the institutional review committees at the California Department of Public Health 
(CDPH) and the University of California, Berkeley.
Subjects
CCLS Hispanic ALL discovery set—The discovery sample includes 321 Hispanic 
participants with ALL and 454 Hispanic controls from CCLS, whose recruitment has been 
described in detail previously (11). This population-based case-control study includes 
subjects from 35 California counties recruited from 1995-2008. Birth certificate information 
obtained from the CDPH was used to select 1-2 controls for each case, matching on date of 
birth, sex, Hispanic ethnicity, and maternal race.
COG/WTCCC ALL validation set—The ALL fine-mapping validation sample includes 
980 European-ancestry children from COG protocols P9904 and P9905. Data were obtained 
from dbGaP study accession phs000638.v1.p1 (Genome-Wide Association Study of Relapse 
of Childhood Acute Lymphoblastic Leukemia), and have been described in detail (12, 13). 
Case-control comparisons were made with 2624 European-ancestry individuals accessed 
from the WTCCC (14). Demographic characteristics of COG cases and WTCCC controls 
appear in Supplementary Table 1.
CCLS multi-ethnic ALL validation set—An additional 111 African-American cases, 
52 Hispanic cases, 154 African-American controls, and 47 Hispanic controls from CCLS 
were genotyped at rs3731249 using a TaqMan assay. These CCLS study participants do not 
overlap with individuals in the discovery sample or the COG/WTCCC validation set.
GENEVA melanoma case-control set—Melanoma case-control data were obtained 
from dbGaP Study Accession phs000187.v1.p1 (High Density SNP Association Analysis of 
Melanoma: Case-Control and Outcomes Investigation). Demographic characteristics of 
these 1969 adult melanoma cases and 1044 controls appear in Supplementary Table 1. These 
samples were genotyped as part of the Gene Environment Association Studies initiative 
(GENEVA) (15).
UCSF/Mayo glioblastoma case-control set—Glioblastoma data were generated via 
pooled deep-sequencing of 684 adults with glioblastoma and 821 controls from the UCSF 
Adult Glioma Study (AGS) and The Mayo Clinic. AGS cases were adults with incident 
histologically-confirmed glioblastoma. AGS controls were matched on age, sex and 
ethnicity (16). Mayo Clinic cases with incident glioblastoma were recruited from 
2005-2012. Mayo controls were consented individuals who had a general medical exam at 
the Mayo Clinic, matched on sex, date of birth (within 2.5 years), self-identified race and 
residence (17). Demographic characteristics of glioblastoma cases and controls appear in 
Supplementary Table 1.
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PanScan pancreatic cancer case-control set—Pancreatic cancer case-control data 
were obtained from dbGaP Study Accession phs000206.v4.p3 [Whole-Genome Scan for 
Pancreatic Cancer Risk in the Pancreatic Cancer Cohort Consortium (PanScan)]. 
Demographic characteristics of these 2273 pancreatic cancer cases and 2418 controls appear 
in Supplementary Table 1. These samples were genotyped as part of the Cancer Genetic 
Markers of Susceptibility (CGEMS) Project (18, 19).
Sample preparation and genotyping
Prediagnositic constitutive DNA for CCLS samples was extracted from neonatal bloodcards 
and genotyped using the Illumina Human OmniExpressV1 platform. DNA extraction was 
performed using the QIAamp DNA Mini Kit (QIAGEN, USA, Valencia, CA). Genotype 
reproducibility was verified using ten duplicate samples with average concordance 
>99.99%. Samples with genotyping call rates <98% were excluded. Samples were screened 
for cryptic relatedness using 10,000 unlinked SNPs and excluded if identity-by-descent was 
>0.15. Samples with discordant sex information (reported vs. genotyped sex) were excluded. 
SNPs with genotyping call rates <98% were excluded. Any SNP with a Hardy-Weinberg 
Equilibrium (HWE) P-value <1×10−5 in controls was excluded. DNA from an additional 
163 CCLS cases and 201 CCLS controls was genotyped for rs3731249 using a TaqMan 
assay (Applied Biosystems: C__25611114_10). These samples were randomized on 96-well 
plates, containing HapMap trios and 5 duplicate samples per plate. All trio genotypes 
displayed Mendelian consistency and duplicates showed genotype concordance. Cluster 
plots were visually inspected.
Constitutive DNA from COG samples was extracted from remission blood, as previously 
detailed (12). DNA samples were genotyped on the Affymetrix 6.0 array and genotype data 
were downloaded from dbGaP accession phs000638.v1.p1. Control genotype data for 
European-ancestry control samples genotyped on the Affymetrix 6.0 array were downloaded 
from the Wellcome Trust Case-Control Consortium (14). Genotyping quality-control 
procedures were conducted independently in cases and in controls. Samples with genotyping 
call rates <98% in cases or controls were excluded. SNPs with genotyping call rates <98% 
were excluded. We excluded subjects showing evidence of non-European ancestry, samples 
with mismatched reported versus genotypes sex, and related subjects (IBD>0.15). SNP data 
were used to ensure no overlap between ALL cases included in validation analyses and 
those included in discovery analyses. COG and WTCCC genotype data were merged to 
create a final set of 980 cases and 2624 European-ancestry controls.
DNA for GENEVA melanoma case-control samples were genotyped using the Illumina 
HumanOmni1-Quad_v1-0_B array. Genotype data were downloaded from dbGaP accession 
phs000187.v1.p1. Samples were filtered based on a pre-computed sample filter provided by 
dbGaP. Subsequently, subjects with genotyping call-rate <95%, discordant genotyped versus 
reported sex, non-European ancestry, or cryptic relatedness were removed from analyses. 
SNPs with genotyping call rates <98% or HWE P-value <1×10−5 (among controls) were 
excluded. The final European-ancestry dataset contained 1969 cases and 1044 controls.
The glioma GWAS association peak on 9p21.3, between 21.930–22.135 Mb, underwent 
targeted deep-sequencing using pooled constitutive DNA from UCSF and Mayo samples. 
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Four pools of DNA were prepared - two from glioblastoma cases (NUCSF=380; NMayo=304) 
and two from controls (NUCSF=547; NMayo=274). These DNA pools were subjected to long-
range PCR covering the association peak, followed by next-generation sequencing to a 
target depth of 2,000X. NGS was performed by deCODE Genetics and subjected to quality-
control measures as previously described (17). Variants were removed that had fewer than 
1000 reads in a sequencing pool. Variants whose allele frequency estimates differed more 
than 10% between the two case pools or between the two control pools were removed.
DNA for PanScan pancreatic cancer case-control samples was genotyped using either the 
Illumina Human550v3 array or the 610QuadV1B array. Genotype data were downloaded 
from dbGaP accession phs000206.v4.p3. Quality-control was conducted separately by array. 
Subjects with genotyping call-rate <98%, discordant genotyped versus reported sex, non-
European ancestry, or cryptic relatedness were removed. SNPs with genotyping call rates 
<98% or HWE P-value <1×10−5 (among controls) were excluded. The final set contained 
2273 European-ancestry cases and 2418 controls.
Statistical analyses
Using Illumina OmniExpress array data (for CCLS discovery samples) or Affymetrix 6.0 
data (COG validation samples), targeted SNP imputation was performed for a 500kb region 
on chromosome nine from 21.735Mb to 22.235Mb (GRCh37/hg19). The region is 
approximately centered on the original ALL GWAS hit in the region (rs3731217), first 
published by Sherborne et al (5). Imputation was performed using the IMPUTE v2.3.1 
software and its standard Markov chain Monte Carlo algorithm and default settings for 
targeted imputation (20). All 1,000 Genomes Phase I integrated haplotypes were provided as 
the imputation reference panel (21). SNPs with imputation quality (info) scores <0.70 or 
posterior probabilities <0.90 were excluded. Association statistics for imputed and directly 
genotyped SNPs were calculated using logistic regression in SNPTESTv2, using an allelic 
additive model (22) and a missing-data likelihood score-test to account for additional 
uncertainty inherent in analysis of imputed genotypes. The first five ancestry-informative 
principal components from Eigenstrat were used as covariates in logistic regression analyses 
of both CCLS discovery and COG validation sets (23). Of note, the rs3731249 missense 
variant that is the focus of this manuscript was directly genotyped on-array and was not 
imputed in the CCLS discovery set.
Case-control associations for CCLS samples undergoing TaqMan genotyping were 
evaluated using logistic regression, assuming an allelic additive model, adjusting for self-
reported ethnicity (African-American or Hispanic). We have previously demonstrated the 
validity of self-reported ethnicity as a measure of genetic ancestry in CCLS (24).
Associations from the CCLS Hispanic discovery set, the COG/WTCCC validation set, and 
the CCLS ALL validation set were combined using fixed effects meta-analysis in the META 
software package to generate a summary odds ratio and P-value for the combined ALL case-
control comparisons (25).
Genome-wide SNP data for melanoma cases and controls were analyzed using logistic 
regression, adjusted for the first five ancestry-informative principal components, using Plink 
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and Eigenstrat (23, 26). As in the CCLS Hispanic discovery set, rs3731249 was directly 
genotyped on-array in the melanoma dataset.
Allele frequencies from the deCODE NGS glioblastoma case-control data were calculated 
based on read counts; separately for reads generated from each case and control pool. Based 
on the derived allele frequencies, the number of chromosomes in the original pools carrying 
various alleles was estimated. Association tests were conducted using Fisher's exact test for 
the estimated number of chromosomes carrying the minor alleles in the corresponding case 
and control pools, with Mayo and UCSF data combined as previously described (17).
Genome-wide SNP data for pancreatic cancer cases and controls were stratified by array 
(550 versus 610Q). Data from each array underwent imputation using the IMPUTE v2.3.1 
software (20) and all 1,000 Genomes Phase I integrated haplotypes (21). Allelic additive 
SNP association statistics were calculated using logistic regression in SNPTESTv2, 
stratified by array (22). Five ancestry-informative principal components from Eigenstrat 
were used as covariates in logistic regression analyses (23). Association statistics from the 
two arrays were combined using fixed effects meta-analysis in the META software package 
(25).
Calculation of ancestral components in CCLS Hispanics
Ancestral components were calculated in Hispanic study subjects using Human Genome 
Diversity Project samples as the reference founder populations (27). A total of 63,303 
autosomal SNPs, common to both datasets, was used to evaluate ancestry using the program 
Structure (28), as previously described (29). Ancestral proportions were compared between 
individuals that carried the rs3731249 risk allele and those that did not carry the risk allele 
using a t-test.
MLPA
Multiplex ligation-dependent probe amplification (MLPA) was performed, as previously 
described, for 848 ALL patients with sufficient bone marrow DNA available(29). MLPA 
was carried out using the SALSA MLPA probemix P335-B1 ALL-IKZF1 (MRC Holland), 
which includes 2 probes within CDKN2A and 1 probe within CDKN2B. Single-gene 
deletions were identified when either the CDKN2A probes or the CDKN2B probe 
exclusively showed evidence of copy-number loss, with the other probe(s) remaining copy-
neutral. Data analysis was carried out using “Coffalyser.Net” fragment analysis software 
(MRC Holland). In brief, peak height ratios were determined by intra-sample normalization 
using data from 13 reference probes in genomic regions known not to be somatically altered 
in childhood ALL, and by inter-sample normalization using data from constitutive DNA 
reference samples.
Assessment of rs3731249 allelic imbalance and copy-number using SMART-ddPCR
We assayed all ALL patients that were heterozygous for rs3731249 and had diagnostic bone 
marrow DNA available (N=37) using a novel application of Droplet DigitalTM PCR 
(ddPCR) (Bio-Rad), termed Somatic Mutation Allelic Ratio Test (SMART-ddPCR). 
SMART-ddPCR was used to assess preferential allelic imbalance (PAI) of the CDKN2A 
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missense SNP rs3731249 in tumor DNA. This allowed assessment of the hypothesis that the 
protective allele of rs3731249 will be preferentially lost in tumors and the risk allele 
preferentially retained.
ddPCR was carried out as previously described (30). The Taqman SNP Genotyping Assay 
for rs3731249 (ABI: C__25611114_10) was used in ddPCR reactions, with FAM- and VIC-
labeled probes for detection of the risk (T) and protective (C) alleles, respectively. For each 
of the samples, ddPCR was carried out in duplicate and data were analyzed using 
QuantaSoftTM Software (Bio-Rad). To determine presence of allelic imbalance, for each 
subject we calculated the proportion of risk allele compared to protective allele as follows:
This results in a proportion between 0 and 1, with an expected proportion of 0.50 for 
samples with no allelic imbalance. Two of the 37 samples were excluded due to low 
concentrations for both the risk and protective alleles in the ddPCR reactions.
To determine thresholds for calling the presence of allelic imbalance in a subject, we 
analyzed constitutive DNA from rs3731249 heterozygotes using ddPCR. We used 3 
standard deviations above and below the mean risk allele proportion in these samples 
(0.491) to define the upper (0.524) and lower (0.458) thresholds, respectively. Tumor 
samples with allelic ratios falling outside this range were considered to demonstrate allelic 
imbalance. Among samples showing allelic imbalance (N=17), the number of tumor samples 
with PAI favoring the risk allele was compared to the number favoring the protective allele 
using a binomial test and assuming, under the null hypothesis, that a sample was equally 
likely to lose one allele as the other (i.e. p=q=0.50).
To assess copy number at the rs3731249 locus, a second ddPCR reaction was carried out 
using a Taqman assay targeting the SLC24A3 gene within a region not known to be copy 
number variable in ALL. Concentration of total CDKN2A relative to concentration of the 
genomic control was calculated as follows:
Tumor samples showing no evidence of copy-number loss but showing allelic imbalance 
were likely to have acquired copy-neutral LOH. Conversely, samples that presented with 
copy number loss but without allelic imbalance were presumed to have subclonal 
homozygous deletions.
RESULTS
Fine-mapping the 9p21.3 association with childhood ALL
Genotype data were generated for 321 Hispanic children with ALL and 454 Hispanic control 
children from CCLS using dried neonatal bloodspot DNA and the Illumina Omni-Express 
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genotyping array (31). Imputation to 1000 Genomes was performed across a 500kb region 
on chromosome nine from 21.735Mb to 22.235 Mb (GRCh37/hg19), encompassing the 
MTAP, CDKN2A, CDKN2B and CDKN2B-AS1 genes and promoters. One-hundred thirty-
seven SNPs in the region were directly genotyped on-array and an additional 1909 were 
successfully imputed. The region is approximately centered on the original ALL GWAS 
lead SNP (rs3731217), first published by Sherborne et al (5).
The tag SNP from the previous GWAS, rs3731217, was associated with ALL risk in the 
CCLS Hispanic case-control data (OR=0.65; P=0.020). Capitalizing on the reduced linkage 
disequilibrium (LD) in the genetically admixed Hispanic discovery set (Figure 2), we 
identified 51 SNPs with p-values <0.020 and effect sizes larger than that observed for 
rs3731217. These SNPs were more strongly associated with ALL than rs3731217, both in 
terms of statistical significance and magnitude of effect, and were carried forward for 
validation in a second, independent case-control set.
Genotype data were generated for 980 European-ancestry children with ALL using 
remission blood samples and the Affymetrix 6.0 array by COG, as previously described 
(12). These 980 ALL cases were combined with 2624 European-ancestry control children 
from the WTCCC to form the validation case-control set (14). Imputation to 1000 Genomes 
was performed across the same 500kb region on chromosome nine. 127 SNPs in the region 
were directly genotyped on-array and an additional 1002 were successfully imputed. Of the 
51 SNPs more strongly associated with ALL risk in the Hispanic discovery data than the 
rs3731217 tag SNP, 46 were successfully genotyped or imputed in the COG/WTCCC 
validation set. Applying a strict Bonferroni correction for 46 tests of association, 42 of these 
SNPs were associated at P<1.1×10−3 in the validation set.
SNP associations from the discovery and validation sets were combined using meta-analysis 
to generate a volcano plot of the joint associations, with effect size plotted on the x-axis and 
statistical significance plotted on the y-axis (Figure 3). The volcano plot highlights the 42 
SNPs identified in discovery analyses and validated in COG data, and reveals three clear 
outliers in tight LD (R2>0.99): rs113650570, rs36228834 and rs3731249.
Bioinformatic, in-silico functional genomic and conditional SNP analyses
The 42 SNPs identified in discovery analyses which were associated at P<1.1×10−3 in the 
validation set appear in Supplementary Table 2. These SNPs were functionally annotated 
using ENCODE2 data, implemented in HaploRegV3 and RegulomeDB (32, 33), and were 
also investigated using data from the Genotype-Tissue Expression (GTEx) project to 
determine if they were cis eQTLs for MTAP, CDKN2A or CDKN2B (34). The three outliers 
identified by the volcano plot (rs113650570, rs36228834 and rs3731249) are more than 
three orders of magnitude more statistically significantly associated with ALL risk than the 
fourth-ranked variant, rs56018935 (Supplementary Table 2). While rs113650570 and 
rs36228834 are intronic SNPs with little direct evidence suggesting a regulatory function 
(Supplementary Table 2), rs3731249 is a p16 missense variant (A148T) in exon 2 of 
CDKN2A (Figure 4).
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Numerous SNPs in the region have putative functional relevance based on their location 
within promoter histone marks, enhancer histone marks, DNase hypersensitivity sites, and 
canonical transcription factor binding motifs. Additionally, a number of linked SNPs are 
significant CDKN2B eQTLs (Supplementary Table 2). Thus, it is possible that a number of 
ALL-associated variants in the region are causally related to leukemogenesis.
Conditional analyses were performed in the discovery and validation datasets to determine 
whether rs3731249 could explain the majority of the ALL association signal in the 9p21.3 
region. Because the three lead SNPs (rs113650570, rs36228834 and rs3731249) are in 
complete LD, conditional analyses are unable to assess their effects independent of each 
other. Adjusting for subject genotype at rs3731249 greatly attenuated SNP associations in 
the region in logistic regression models (Figure 5). After adjusting for rs3731249, the most 
significantly associated SNP in meta-analysis of the two datasets was rs2188127, an 
intergenic variant between MTAP and CDKN2A (P=1.1×10−4, OR=0.73, 95% 
CI=0.62-0.86). Prior to adjustments for rs3731249, 54 SNPs had smaller p-values in the 
meta-analysis. These conditional analyses indicate that rs3731249, or a variant in tight LD, 
underlies the CDKN2A association signal in the region.
Association of rs3731249 with childhood ALL
In the CCLS Hispanic discovery set, the minor (T) allele of the missense SNP rs3731249 
was associated with a nearly 3-fold increased risk of ALL (OR=2.77; 95% CI=1.58-4.85; 
P=3.78×10−4). Hispanic subjects carrying the rs3731249 risk allele had genomes that were 
more European than individuals not carrying the risk allele, among both cases and controls 
(63.1% European versus 56.2% European; P=5.6×10−3). This 7% increase in European 
genomic ancestry also corresponded to a 7% decrease in Native American genomic ancestry. 
The association between the rs3731249 risk allele and increased European ancestry suggests 
that this allele originated on a European haplotype. The higher risk allele frequency in 
European-ancestry genomes also suggests that rs3731249 may be an ALL risk factor in 
additional populations harboring European ancestry, including non-Hispanic whites and 
African-Americans.
In the European-ancestry COG validation set, the minor allele of missense SNP rs3731249 
was also associated with a 3-fold increased risk of ALL (OR=2.99; 95% CI=2.10-4.26; 
P=1.51×10−9). Along with the two intronic SNPs rs113650570 and rs36228834, this was the 
most statistically significant association in the validation set.
TaqMan genotyping of a third ALL case-control set of Hispanic and African-American 
children (163 cases, 201 controls) again confirmed the 3-fold increased risk associated with 
rs3731249 (OR=3.59; 95% CI=1.22-10.59; P=8.8×10−3). Meta-analysis of the association 
between rs3731249 and ALL risk, across the three ALL case-control sets, reached genome-
wide statistical significance (Pmeta=1.69×10−13; ORmeta=2.97; 95% CI=2.22-3.96).
There was no heterogeneity of effect between B-cell and T-cell ALL in CCLS subjects, but 
rs3731249 did have a larger effect size within certain molecularly-defined ALL subgroups 
(29). Rs3731249 was associated with a 4.5-fold increased risk of ALL harboring a somatic 
CDKN2A deletion (OR=4.5; P=6.4×10−3), a 6-fold increased risk of IKZF1-deleted ALL 
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(OR=6.3; P=1.9×10−3) and a 6-fold increased risk of KRAS- or NRAS-mutated ALL 
(OR=6.4; P=6.1×10−4). Effect sizes were similar in high-hyperdiploid ALL as in the ETV6-
RUNX1 fusion ALL subgroup (OR=2.7 and 2.0, respectively).
MLPA assessment of 9p21.3 focal deletions
We assessed frequency of somatic 9p21.3 deletions in 848 ALL tumor specimens from the 
CCLS using MLPA, and identified 256 with copy-number loss at 9p21.3 (30.2%). 33 of 
these samples had focal single-gene deletions, of which 27 exclusively affected CDKN2A 
and 6 exclusively affected CDKN2B, suggesting that CDKN2A is the principal target of 
9p21.3 deletions in ALL (P=3.0×10−4).
Preferential allelic imbalance of the rs3731249 risk allele in ALL tumors
Because a heritable CDKN2A missense variant was strongly and robustly associated with 
increased ALL risk in three case-control sets, and ALL tumors frequently harbor somatic 
alterations of CDKN2A, we sought to determine if the risk allele is preferentially retained 
(and the protective allele preferentially lost) in ALL tumors. To investigate this interface of 
heritable and acquired CDKN2A variation in leukemogenesis, we assessed preferential 
allelic imbalance of rs3731249 using droplet digital PCR. This assay, termed “SMART-
ddPCR” (see Methods), was used to measure the relative number of copies of the T and C 
alleles in constitutive DNA and in leukemia diagnostic bone marrow samples (i.e. tumor 
DNA) in a subset of CCLS cases. Copies of the rs3731249 risk (T) and protective (C) allele 
were approximately equal in diploid constitutive DNA from heterozygous patients, as 
anticipated, with a mean risk allele proportion of 0.491 and upper and lower thresholds of 
0.524 and 0.458 respectively (Figure 6).
A total of 57 ALL patients from CCLS were heterozygous for the rs3731249 risk allele in 
Illumina GWAS genotyping or targeted TaqMan genotyping. Sufficient tumor tissue was 
available for 35 of these patients, of which 17 showed evidence of allelic imbalance due to 
hemizygous deletion (N=11) or copy-neutral LOH (N=6). Of these 17 tumors with allelic 
imbalance, 14 preferentially retained the risk allele and 3 preferentially retained the 
protective allele (PBinomial=0.006) (Figure 6). This indicates that the rs3731249 missense 
SNP is subject to directional selection, wherein the ALL risk allele is favored during clonal 
evolution of the tumor. The 18 tumor samples that did not display allelic imbalance either 
had no detectable 9p21.3 lesions (N=13) or had subclonal homozygous deletion (N=5), 
suggesting a complex assortment of somatic CDKN2A alterations in leukemogenesis.
9p21.3 association mapping in additional cancers
Germline mutations in CDKN2A are associated with familial melanoma-astrocytoma 
syndrome (35) and familial melanoma-pancreatic cancer syndrome (36). Additionally, the 
cancer-associated GWAS hits on 9p21.3 span 320kb from a melanoma-associated variant at 
rs7023329 near MTAP(6) to a glioma-associated variant at rs4977756 in CDKN2B-AS1(7). 
The ALL association peak in CDKN2A partially overlaps the melanoma and glioma peaks, 
suggesting that pan-cancer risk alleles may reside in the region (Figure 7). To determine if 
the putatively hypomorphic rs3731249 variant is associated with adult melanoma, 
glioblastoma, or pancreatic cancer risk, we used data from three large case-control studies of 
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European-ancestry populations. Among 1969 adults with melanoma and 1044 controls 
genotyped on-array, strong association was detected in MTAP (Pmin=5.5×10−7. However, no 
significant associations were detected in CDKN2A, including at missense variant rs3731249 
(P=0.52) (Figure 7a). Pooled deep-sequencing of the 9p21.3 region in 684 adults with 
glioblastoma and 821 controls identified strong association in CDKN2B-AS1 
(Pmin=8.2×10−8. However, rs3731249 was not significantly associated with glioblastoma 
risk (P=0.52) (Figure 7c). Among 2273 adults with pancreatic cancer and 2418 controls 
genotyped on-array, no 9p21.3 SNPs had P-values <0.05, including rs3731249 (P=0.15) 
(data not shown in figure).
We also sought to determine if the lead SNPs from melanoma and glioblastoma case-control 
analyses are associated with ALL risk. The lead melanoma SNP from previous GWAS, 
rs7023329, was not associated with ALL risk in meta-analysis of the CCLS and COG 
datasets (OR=0.93; P=0.15). Similarly, the lead glioblastoma SNP from previous GWAS, 
rs4977756, was not associated with ALL risk in meta-analysis of the CCLS and COG 
datasets (OR=0.99; P=0.79).
DISCUSSION
We have refined the childhood ALL association peak at chromosome 9p21.3 via genotyping 
and fine-mapping, revealing a heritable p16 missense variant rs3731249 (A148T) that 
confers a 3-fold increased risk of childhood ALL, consistent across three ALL case-control 
sets with European ancestry or admixture. Adjusting for rs3731249 removed the majority of 
the association signal at chr9p21.3. Identifying a missense variant with such a large effect on 
ALL risk, and one that has not been previously reported, demonstrates the utility of fine-
mapping known association loci through a combination of genotyping and imputation with 
whole-genome sequencing datasets, as well as the value of genetically admixed populations 
for identifying putatively causal variants.
Using several online tools, we assessed whether the amino acid change from alanine to 
threonine affects the protein function of p16, but found no evidence of any strong 
deleterious effects (37, 38). However, evidence from previous studies suggests that 
p16(A148T) may result in reduced efficiency of p16 as a cell cycle inhibitor. The variant 
protein has been shown to have diminished ability to compete with cyclin D for CDK4 
binding (39) and has altered subcellular localization and expression relative to wild-type p16 
(40). The 2% risk allele frequency observed in healthy controls suggests that the effect of 
A148T on p16 activity is likely subtle and may only become important in the context of a 
pre-cancerous lymphoblast. Furthermore, rs3731249 was not associated with risk of 
melanoma, glioblastoma, or pancreatic cancer. This suggests rs3731249 may be associated 
with risk of cancer only in tissues that constantly self-renew, such as the bone marrow, but 
not associated with risk of cancer in tissues with low rates of self-renewal, such as glia and 
melanocytes (41, 42).
SNPs on 9p21.3 have been associated with multiple cancers and as a variety of other 
medical conditions, including heart disease, stroke, diabetes, and glaucoma (14, 43-45). The 
widely assorted localization of these associations suggests multiple functional genetic 
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polymorphisms exist in the region, and also highlights the core pleotropic functionality of 
genes on 9p21.3.
The second exon of CDKN2A encodes portions of both the p14 and p16 proteins. Although 
the rs3731249 polymorphism is within exon two, it is positioned outside of the p14 coding 
region and is therefore unlikely to affect function of that protein (Figure 4). This suggests 
that p16, and not p14 or p15, is the critical mediator of leukemogenesis in the 9p21.3 region. 
This is further supported by the MLPA data which demonstrated that CDKN2A, and not 
CDKN2B, was the target of focal single-gene deletions in the region.
Heritable genetic variants have recently been associated with specific subtypes of childhood 
ALL, with the GATA3 rs3824662 risk allele associated exclusively with genomic alterations 
that underlie Philadelphia chromosome-like ALL (4) and PIP4K2A SNPs associated 
exclusively with high-hyperdiploid ALL (46). However, the effects of these variants on 
subtype-specific somatic alterations have yet to be elucidated. In this study, we identify a 
CDKN2A missense variant that confers high risk of ALL and even higher risk of CDKN2A-
deleted ALL, suggesting that the risk variant may initiate a molecular cascade enhanced by 
subsequent deletion. Furthermore, we demonstrate a direct interaction between heritable and 
somatic genetic variation in CDKN2A, made evident in the form of PAI.
We developed a novel methodology, SMART-ddPCR, to investigate PAI of cancer-
associated heritable variants via absolute measurement of risk and protective allelic copy 
number. We demonstrate that in childhood ALL tumor samples, there is preferential 
retention of the risk allele and loss of the protective allele among rs3731249 heterozygotes 
with somatic CDKN2A alterations, suggesting an important role for this missense SNP in 
leukemia etiology and progression. Of twenty-one heterozygotes that did not display PAI for 
the rs3731249 risk allele, five were observed to have subclonal homozygous deletion of 
CDKN2A, thereby inactivating both alleles. Another three subjects had deletion of RB1, 
suggesting that subjects not displaying PAI may have CDKN2A point mutations or 
alterations to other genes involved in control of cell cycle.
The complexity and subclonality of somatic CDKN2A alterations as revealed by our 
SMART-ddPCR data support current evolutionary theories of cancer development. It has 
recently been shown that CDKN2A deletions can be caused by off-target RAG-mediated 
mutational processes (47), which could result in hemizygous or homozygous CDKN2A loss, 
or in copy-neutral LOH via attempted repair of hemizygous deletions. The initial event may 
be random (i.e. deletion of the rs3731249 risk allele is just as likely as the protective allele), 
but tumor cells retaining the risk allele have a competitive advantage during tumor 
evolution. Our results provide evidence that heritable genetic variation can act as an 
additional substrate for selection during clonal evolution of childhood ALL.
The rs3731249 risk allele is found at a frequency of 2% in healthy control children. Such 
common variants do not often have such large effect sizes. However, a SNP in the 3’-UTR 
of TP53 was recently shown to confer 3-fold increased risk of basal cell carcinoma, 
neuroblastoma, and glioma (48-50). Our data reveal that p16 missense SNP rs3731249 
confers a 3-fold increased risk of ALL in three independent and ethnically diverse case-
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control sample sets. Furthermore, this variant is subject to directional selection during tumor 
evolution. These results demonstrate, for the first time, a direct interaction between heritable 
and somatic CDKN2A variation underlying leukemogenesis.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Summary of study design and analyses
The flowchart details progression of subjects and analyses through various stages of the 
study.
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Figure 2. Ethnic-specific patterns of linkage disequilibrium in the 9p21.3 region
(A) Haplotype structure in the California Childhood Leukemia Study Hispanic discovery set 
(Ncases=321, Ncontrols=454). (B) Haplotype structure in the Children's Oncology Group and 
Wellcome Trust Consortium validation set (Ncases=980, Ncontrols=2624). Darker shading 
indicates higher R2 values and greater correlation between SNPs.
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Figure 3. Volcano plot of SNP associations from case-control analyses of California Childhood 
Leukemia Study (CCLS) participants and Children's Oncology Group (COG) participants
SNP associations from CCLS Hispanics and COG European-ancestry subjects were 
combined via meta-analysis then plotted with -log10(P-values) on the Y-axis and ln(odds 
ratio) on the X-axis. The open black circle denotes rs3731217, the ALL tag-SNP identified 
in previous GWAS. 42 SNPs having smaller p-values and larger effect sizes than GWAS tag 
SNP rs3731217 in CCLS discovery analyses, and also associated at P<1.1×10−3 in COG 
validation analyses, appear as black diamonds. Three outlier associations are labeled with 
their rsID.
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Figure 4. Representation of the coding sequences of the CDKN2A gene
Transcripts 1-5 are p16 splice variants and transcript 6 is the p14ARF (Exon 1 not pictured). 
Light green blocks depict coding exons. Dark green blocks are untranslated. The red vertical 
line indicates the position of the rs3731249 missense variant. This polymorphism alters 
amino acid coding (Alanine → Threonine) in p16 splice variants 1, 2, 4, and 5, but not in 
splice variant 3 or in p14ARF. Gene transcript data were extracted from the NCBI Homo 
sapiens Annotation Release 105.
Walsh et al. Page 20
Cancer Res. Author manuscript; available in PMC 2016 November 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 5. SNP association plots for ALL risk at 9p21.3 in meta-analysis of CCLS Hispanic 
discovery set and the COG/WTCCC validation set, both with and without adjustment for 
missense variant rs3731249
The strength of linkage disequilibrium between each SNP and missense variant rs3731249 
(purple circle) is indicated by color. Recombination rates, plotted in light blue, are based on 
1000 Genomes CEU samples. (A) Association plot for ALL risk in the combined CCLS 
Hispanic discovery set and COG validation set. (B) Association plot for ALL risk in the 
combined CCLS Hispanic discovery set and COG validation set, adjusted for rs3731249 
genotype.
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Figure 6. Risk allele proportions in constitutive and tumor DNA from ALL patients 
heterozygous for the rs3731249 missense variant
Risk allele proportions are displayed as a fraction of total allelic copy number measured 
using ddPCR. Subjects were assayed in duplicate, and error bars represent standard error of 
the mean. Upper/lower thresholds of allelic imbalance (AI) were determined from repeat 
measurements of constitutive DNA samples (white squares). In tumor DNA, 14 patients 
showed AI favoring the rs3731249 risk allele versus 3 patients with AI favoring the 
protective allele (PBinomial=0.006).
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Figure 7. SNP association plots for risk of melanoma, childhood ALL, and glioblastoma at 
9p21.3
The strength of LD between each SNP and missense variant rs3731249 (purple circle) is 
indicated by color. Recombination rates, plotted in light blue, are based on 1000 Genomes 
samples. (A) SNP association plot for melanoma risk among 1969 cases and 1044 controls 
of European-ancestry. (B) SNP association plot for childhood ALL risk from a meta-
analysis of 321 cases and 454 controls from the CCLS Hispanic GWAS and 980 cases and 
2624 controls from COG/WTCCC. (C) SNP association plot for glioblastoma risk among 
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684 patients and 821 controls of European-ancestry from the UCSF Adult Glioma Study and 
The Mayo Clinic.
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